OUR PIPELINE We think differently and innovate relentlessly in pursuit of elegant solutions to the most difficult challenges facing patients. Our next-generation therapeutics are transforming patient care today. Our cutting-edge science serves as the foundation for a deep and diverse pipeline of small-molecule and protein therapeutics focused on significant unmet medical needs – a pipeline of first-in-class drugs with new mechanisms of action that target previously untapped receptors and enzymes. Omeros has retained exclusive control of worldwide commercial rights for all products, product candidates, and programs. Therapeutic Area no filters Phase no filters Antibody Small Molecule Download full PDF Print OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3%, for addition to ocular irrigating solution Marketed Cataract surgery or intraocular lens replacement Narsoplimab (MASP-2 inhibitor, lectin pathway) Phase 3 Hematopoietic Stem Cell Transplant-Associated TMA (HSCT-TMA) Phase 3 IgA Nephropathy (IgAN) Phase 3 Atypical Hemolytic Uremic Syndrome (aHUS) Phase 2 Lupus Nephritis & Other Renal Diseases OMS405 (PPARγ) Phase 2 Opioid and Nicotine Addiction OMS527 (PDE7 inhibitor) Phase 1 Addictions and Compulsive Disorders; Movement Disorders OMS906 (MASP-3 inhibitor, alternative pathway) Phase 1 PNH and a Wide Range of Other Alternative Pathway Disorders MASP-2, MASP-3, MASP-2/3 Preclinical Disorders of the Lectin and Alternative Pathways of Complement Small-molecule inhibitors of MASP-2, MASP-3, MASP 2/3 As part of lifecycle planning for narsoplimab we are developing a long-acting second-generation antibody against MASP-2 designed for subcutaneous administration which is targeted for clinical entry early in 2022, followed by our orally available small-molecule inhibitor of MASP-2. We are also developing small-molecule inhibitors of MASP-3 and bispecific inhibitors of MASP-2/-3. GPR174 Preclinical Cancer GPR161 Preclinical Cancer Related Pages RESEARCH AREAS DISCOVERY TECHNOLOGIES ©2020 Omeros Corporation, All rights reserved. Site Map Contact Us Privacy Policy Legal We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. If you continue to browse this site, you will accept our use of cookies. For more information, please read our Privacy Policy. AGREE

SITE MAP About Omeros About Omeros Leadership Science Research Areas Discovery Technologies Scientific Publications Pipeline Pipeline Overview OMIDRIA® Narsoplimab (OMS721) OMS405 OMS527 OMS906 MASP-2, MASP-3, MASP-2/3 GPR174 GPR161 Product OMIDRIA® Medical Information Request Patients Commitment to Patients Investors & News Careers Contact Us ©2020 Omeros Corporation, All rights reserved. Site Map Contact Us Privacy Policy Legal We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. If you continue to browse this site, you will accept our use of cookies. For more information, please read our Privacy Policy. AGREE